nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S – Share repurchase programme
June 06, 2023 05:56 ET | Novo Nordisk A/S
Bagsværd, Denmark, 6 June 2023 – On 9 May 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk enters exclusive negotiations to acquire a controlling stake in BIOCORP, to be followed by a tender offer on all remaining shares
June 05, 2023 01:02 ET | Novo Nordisk A/S
Novo Nordisk has entered into exclusive negotiations with BIO JAG, BIOCORP’s main shareholder, for the purchase of its entire stake in BIOCORP, representing 45.3% of its share capital and 62.2% of its...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S - share repurchase programme
May 30, 2023 06:50 ET | Novo Nordisk A/S
Bagsværd, Denmark, 30 May 2023 – On 9 May 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk and Life Edit Therapeutics establish multi-target collaboration to discover and develop gene editing therapies for rare and cardiometabolic diseases
May 24, 2023 05:58 ET | Novo Nordisk A/S
Life Edit will receive an upfront cash payment and is eligible to receive milestone payments of 250-335 million US dollars for each of seven development programmes, as well as tiered royalties on...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S: Oral semaglutide 50 mg achieved 15.1% weight loss (17.4% if all people adhered to treatment) in adults with obesity or overweight in the OASIS 1 trial
May 22, 2023 10:01 ET | Novo Nordisk A/S
Bagsværd, Denmark, 22 May 2023 – Novo Nordisk today announced headline results from OASIS 1, a phase 3a trial in the global OASIS programme. OASIS 1 is a 68-week, efficacy and safety trial comparing...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S - share repurchase programme
May 22, 2023 08:37 ET | Novo Nordisk A/S
Bagsværd, Denmark, 22 May 2023 – On 9 May 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
May 15, 2023 09:56 ET | Novo Nordisk A/S
Bagsværd, Denmark, 15 May 2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S - share repurchase programme
May 15, 2023 09:47 ET | Novo Nordisk A/S
Bagsværd, Denmark, 15 May 2023 – On 9 May 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
May 10, 2023 07:10 ET | Novo Nordisk A/S
Bagsværd, Denmark, 10 May 2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons...
nn_logo_cmyk_blue_small.jpg
Trading in Novo Nordisk shares by board members, executives and associated persons
May 09, 2023 14:06 ET | Novo Nordisk A/S
Bagsværd, Denmark, 9 May 2023 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance...